RT101 Basic Therapeutics

Download Report

Transcript RT101 Basic Therapeutics

RT 210 Pharmacology

Terminology

   Drug  Exerts biological effect used for Treatment   Diagnosis Prevention  Chemical name Chemical structure of the drug

Terminology

      Generic name Name given by US Pharmacopoeia Trade name Brand or patented name Side effect: Other than desired effects Half life: Length of time when 1/2 dosage is still active in the body

  

Terminology

Tolerance: A condition in which the dose of a drug must be increased (over time) to obtain the desired effect -or- a decreasing intensity of responsiveness to a drug over time Tachyphylaxis: Rapidly developing tolerance to a drug -or- a rapid decrease in responsiveness to a drug.

Additive effects: The effect of two chemicals acting simultaneously on the same receptors & is the simple sum of the effects that they would have if acting alone

Terminology

Synergism: The presence of one chemical that enhances the effects of the second. Also, when 2 drugs act on a target organ by different mechanisms of action & the effect of the pair is greater than the sum of the separate effects of the drugs.

Terminology

POTENTIATION :

Special case of synergism in which one drug has no effect, but can increase the activity of the other drug. Also, the action of these two drugs result in the total effect being greater than the sum of the independent effects.

Terminology

   Pharmaceutical phase: Method by which a drug is delivered Inhalation (Benefits)     Immediate onset of action at desired site Reduced systemic side effects Smaller doses required Ability of patient to self administer Pharmacokinetic phase: Time required for drug absorption, distribution, metabolization, and excretion

Terminology

   Pharmacodynamic phase: Mechanism of action by which a drug causes its therapeutic effect Agonist: A substance that binds to a receptor and triggers a response in the cell Antagonist: A substance that binds to a receptor but fails to activate the receptor and actually blocks it from activation by agonists

Prescription requirements

     Patient name Drug name Dose Frequency Route of administration

Check before administering drug

      Chart for information Patient's name band Medication label Dates of expiration or opening of the drug Dosage Response to previous administration of drug

      

Normal routes of administration (fastest to slowest)

IV (intravenous) Inhaled (aerosol to lung) IM (intramuscular) Sub Q (subcutaneous injection) Sublingual or rectal absorption Oral Topical

Concentration

  The concentration is the percent solution of the active ingredient in the drug   It is the weight (in grams or mg) of solute dissolved in a volume (in ml) of solvent expressed as a percentage 1% solution means that 1 gram (1000mg) of solute is dissolved in 100 ml of solvent 1000 mg/100 ml = 10 mg/ml

   It is possible to determine the amount of solute or solvent needed in a solution of a known percentage   Before you can determine the amount of solute or solvent that is needed you must first express the concentration as mg/ml Multiply the percentage by 10 i.e. 1% * 10 = 10 mg/ml 0.5% * 10 = 5 mg/ml

Determine what you are trying to find Solute (mg) = solvent (ml) * concentration (mg/ml) You have 1 ml of a 1% solution. How much solute do you need?

1% * 10 = 10 mg/ml Y Y mg = 1 ml * 10 mg/ml Y Solvent (ml) = solute (mg) ÷ concentration (mg/ml) You have 5 mg of a 1% solution. How much solvent do you need?

1% * 10 = 10 mg/ml ml = 5 mg ÷ 10 mg/ml Y mg = 10 mg ml = 0.5 ml

Ratios

     Drug solutions may be expressed as a ratio instead of a percentage A 1:100 solution is a 1% solution and a 1:200 solution is a 0.5 % solution This is derived by the following equation for a 1:100 solution 1/100 = 0.01 then multiply by 100 to give a percentage  Thus 0.01 * 100 = 1% For a 1:200 solution we do the same thing 1/200 = 0.005 then we multiply that by 100 Thus 0.005 * 100 = 0.5%

Ratios

  We can determine the desired solute or solvent with a simple equation  Solution   10 ml of a 1:100 solution. How much solute do we need?

Convert the 1:100 ratio into grams per ml Take 1 and multiply it by 1000 to give us 1000 mg  Add ml to 100 so now we have 1000 mg/100 ml

Ratios

1000

mg

100

ml

Y mg

10

ml

1000

mg

* 10

ml

Y mg

100 100

ml mg

Y mg

Solvent

  10 mg of a 1:200 solution. How much solution do we need?

Set up the equation as before 1000

mg

200

ml

 10

mg Y ml

200

ml

* 10

mg

Y ml

2

ml

1000

mg

Y ml

Nervous system

        Sympathetic nervous system Adrenergic Uses epinephrine as a neurotransmitter Fight or flight Dilates pupils Dilates bronchioles Speeds up heart rate Secretes adrenaline

Nervous system

       Parasympathetic nervous system Cholinergic Uses acetylcholine as a neurotransmitter Feed or breed Constricts pupils Constricts bronchioles Slows down heart rate

Nervous system

  Adrenergic stimulation    Three adrenergic receptors Alpha: Vasoconstriction Beta 1: Increased cardiac rate and strength of contraction Beta 2: Bronchodilation

Nervous system

  Adrenergic stimulation (cont)  Stimulation of receptors with sympathomimetic drugs causes Activation of adenylate cyclase   Increase conversion of atp into cyclic 3'5'amp Results in bronchodilation

Nervous system

  Adrenergic stimulation (cont)  Post stimulation Phosphodiesterase converts cyclic 3'5'amp into 5'amp  Break down of cyclic 3'5'amp ends bronchodilation

Cholinergic stimulation

     Nicotinic receptors Stimulation affects all of the PNS and also affects the sympathetic nervous system and skeletal muscles Causes paralysis of skeletal muscles Increases production of dopamine (pleasure response) Muscarinic receptors :Stimulation of receptors stimulates only the PNS

Specific sympathomimetics

   Isoproterenol HCl Trade name – Isuprel Generic - Isoproterenol HCl     Concentration - 1:200 (0.5%) solution  Receptor effects Alpha 0   Beta1 4+ Beta 2 4+ Short duration Dosage: 0.25-0.5 ml QID or q 4 hours

Specific sympathomimetics

     Isoetharine Trade name: Bronkosol Generic – Isoetharine Concentration – 1:100 (1%) solution  Effects Alpha 0   Beta1 1+ Beta2 3+  Duration – medium

Specific sympathomimetics

  Isoetharine (cont)  Dosage 0.25-0.5ml QID  1cc maximum

Specific sympathomimetics

       Metaproterenol sulfate   Trade Alupent Metaprel Generic - Metaproterenol sulfate Concentration – 5% solution    Effects Alpha – 0 Beta1 - 2+ Beta2 - 2+   Medium duration (2 – 4 hrs) Dosage 0.2 - 0.3 ml tid, qid Maximum dose is 0.3 ml

Specific sympathomimetics

      Racemic epinephrine    Trade name Vaponephrine Micronephrine Asthmanephrine Generic - Racemic epinephrine Concentration - 2.25%    Receptor effects Alpha 2+ Beta1 3+ Beta2 2+ Duration of 0.5 - 2 hours  Dosage: 0.25 - 0.5 ml q1-2 hours

Specific sympathomimetics

      Epinephrine HCl     Trade – Adrenalin Generic Epinephrine HCl Receptor effects Alpha - 3+ Beta1 - 4+ Beta2 - 3+ Concentration - 1:100 (1%) solution Short duration  Dosage: 0.2 – 0.5 ml q2-4 hours

Specific sympathomimetics

     

Salbutamol, Albuterol

Trade name   Ventolin Proventil  Generic name International – salbutamol  US – albuterol Receptor effects    Alpha – 0 Beta1 - 1+ Beta2 - 4+ Concentration - 1:200 (0.5%) solution   Long duration Dosage MDI 2 puffs TID, QID 0.5 ml TID, QID

Specific sympathomimetics

      

Terbutaline sulfate

  Trade name Bricanyl Brethine Generic name - terbutaline sulfate Receptor effect    Alpha – 0 Beta1 - 1+ Beta2 - 3+ Concentration - 200 µg/puff Long duration Dosage: 2 puffs q4-6 hours

Specific sympathomimetics

  Levalbuterol Trade name: Xopenex       (R)-Isomer of Albuterol Very specific Beta2 agonist Same Beta2 as Albuterol No Alpha effects and almost no Beta1 effects   Dosage 0.63 mg every 6 to 8 hours 1.25 mg TID Long duration

Specific sympathomimetics

      Side effects of adrenergic bronchodilators Palpitations Tachycardia Hypertension Restlessness Fear      Anxiety Tremor Weakness Dizziness Pallor

Xanthines

   Inhibits phosphodiesterase thus maintaining levels of cyclic 3'5'amp This results in better bronchodilation  Types Theophylline: Available in tablet and elixir form    Aminophylline Administered IV or in tablet form After a loading dose, serum levels are monitored  Therapeutic serum level of 10-20 mg/dl

Xanthines

       Side effects Dizziness Headache Restlessness Palpitations, tachycardia Nausea, vomiting Anorexia

 

Xanthines

Many physicians now disregard this agent as a choice to treat asthma routinely  Has found favor in treating acute asthma attacks with hospital admittance Subcutaneous Epinephrine as the first agent to try in Status Asthmaticus is often favored

Parasympatholytics/anticholinergic

  Enhance sympathetic effects  Atrovent Ipratropium bromide     Contraindications  Allergy to soybeans and peanuts Blocks production of cGMP Side effect: occasional dry mouth Often used in conjunction with albuterol to enhance bronchodilation

Parasympatholytics/anticholinergic

     Atropine Atropine sulfate Frequently used in surgery    Blocks production of cGMP Contraindications Sensitivity Glaucoma Tachycardia

Parasympatholytics/anticholinergic

  Atropine (cont)  Side effects Dilated pupils     Thick drying of secretions Dry mouth Palpitations Tachycardia

Corticosteroids

  Used in the management of the inflammatory process associated with asthma, reactive airway disease, and other pulmonary disorders Administered orally or aerosolized

Corticosteroids

   Side effects   Inhaled Oral candidiasis Throat irritation  Dry mouth   Systemic Cushing’s syndrome Immunosuppression  Diabetes

Corticosteroids

  Aerosolized steroids  Dexamethasone Decadron   MDI provides 84 µg per inhalation   Dosage 3 to 4 puffs 3 to 4 times a day Not to exceed 12 puffs per day

Corticosteroids

  Aerosolized steroids (cont)  Beclomethasone diproprionate Vanceril, beclovent   MDI provides 42 µg per inhalation   Dosage 2 puffs 3 to 4 times a day Not to exceed 12 puffs per day

Corticosteroids

  Aerosolized steroids (cont)  Flunisolide Aerobid   MDI provides 250µg per inhalation   Dosage 2 puffs 2 times a day Not to exceed 4 puffs per day

 

Corticosteroids

 Aerosolized steroids (cont)  Triamcinolone acetonide Azmacort,   MDI provides 100 µg per inhalation   Dosage 2 puffs 3 to 4 times a day Not to exceed 12 puffs per day Budesonide - Pulmicort Respules - 0.25 mg/2 ml , 0.5 mg/2 ml Turbuhaler – (DPI) 1-2 inhalations twice daily

Corticosteroids

  Aerosolized steroids (cont)  Fluticasone propionate Flovent   MDI provides 44, 110, or 220 µg per inhalation   Dosage 2 puffs of 44 µg 2 times a day for mild asthma 4 puffs of 220 µg 2 times a day for severe asthma

Corticosteroids

    Oral steroids   Reduce inflammation Potentiation of sympathomimetics Dosage    Prednisone Action Loading dose of 4 mg per kg of body weight Maintenance dose of 1 mg per kg Therapeutic serum levels: 100 to 150 mcg/100ml  May be given for a 2-3 week period or long term  To manage the patient’s condition more adequately

Long acting bronchodilators

  Salmeterol xinafoate Serevent        DPI provides 50 µg per blister 1 blister BID MDI provides 25 µg per puff 2 puffs BID 12 hour duration 20-60 minute onset Maintenance therapy only – not for emergency

Long acting bronchodilators

       Formoterol Foradil Dpi provides 12 µg per puff 1 puff bid 12 hour duration 15 minute onset Even though rapid onset and peak effect, better maintenance drug than rescue agent

Prophylactic

   Fluticasone propionate/salmeterol    Advair DPI – discus 100 µg Flovent/50 µg serevent BID 250 µg Flovent/50 µg serevent BID 500 µg Flovent/50 µg serevent BID  Maintenance only – not for emergency

Prophylactic

          Cromolyn sodium Intal Stabilizes mast cell thus preventing histamine release (degranulation) Indicated for management of chronic extrinsic asthma and is also effective as a prophylactic in patients who have intrinsic asthma Prophylactic effects require 2 to 4 weeks to reach maximal levels Not to be used during acute attack MDI provides 800 µg per puff 2 puffs QID SVN with one 20 mg ampule 1 ampule QID

Prophylactic

        Nedocromil sodium Tilade Stabilizes mast cells and has some anti-inflammatory properties Indicated as part of treatment regimen for management of chronic allergic bronchitis and asthma Blocks early and late asthmatic responses to a variety of allergic and nonallergic triggers Prophylactic effects require 2 to 4 weeks to reach maximal levels MDI provides 1.75 mg per puff 2 puffs QID

Leukotriene inhibitors

      Leukotrienes are mediators of inflammation, edema, and bronchoconstriction Leukotriene activity can be inhibited by synthesis inhibition or by receptor blocking Types       Zafirlukast Accolate 20 mg tablets BID Montelukast Singulair 10 mg tablets once a day Zileuton Zyflo 600 mg tablets QID

Antimicrobial agents

      Antibiotics     Tobramycin - TOBI Gentamicin Treats most gram-negative organisms Pseudomonas aeruginosa : Often seen in CF patients Acinetobacter Klebsiella Enterobacter Treats some gram-positive organisms: Staphylococcus aureus Usually preceded by a bronchodilator

Antimicrobial agents

   Antiviral  Ribavirin Treatment of respiratory syncytial virus (RSV)   Causes bronchiolitis in infants Indicated only in carefully selected infants and young children with severe lower respiratory tract infection Delivered with a small particle aerosol generator (SPAG)

Antimicrobial agents

 Antiprotozoal Pentamidine isethionate (Nebu Pent)      Treat opportunistic pneumonia caused by pneumocystis carinii Seen in immunocompromised patients such as AIDS Must be given via a nebulizer with several one-way valves and a scavenging expiratory filter – in a negative pressure room or via portable filter system 300mg (powder form) w/6ml Sterile Water Treatment lasts about 15-20minutes

Antimicrobial agents

      Surfactant Replacement Therapy Premature or low birth weight infants often develop IRDS Primary cause is lack of surfactant at birth Survanta and Exosurf Neonatal Instilled via an ETT followed by manual ventilation and positional changes Restores WNL Lung Compliance in RDS of the newborn

   

Equipment for administering bronchodilator treatments

Small volume nebulizers Metered dose inhalers (MDI) Dry powder inhalers (DPI) Spacers

Mucokinetics (to move mucus)

   Diluents – wetting agents     Thins the mucus making it easier to move Distilled water Used in humidifiers Osmolarity – hypotonic Will be absorbed into interstitial space of tissue May cause edema

Mucokinetics (to move mucus)

  Diluents – wetting agents (cont)  Isotonic saline 0.9% saline    Normal saline Used as diluent for medication Osmolarity - same as lung

Mucokinetics (to move mucus)

  Diluents – wetting agents (cont)   Hypotonic saline Less than 0.9% saline ½ normal saline, 0.45% saline    Osmolarity - hypotonic will be absorbed into the interstitial space Used in USN due to evaporation of water from small particles thus becoming isotonic by the time it reaches the patient Can increase airway resistance

Mucokinetics (to move mucus)

  Diluents – wetting agents (cont)  Hypertonic saline Greater than 0.9% saline      Usually 5% saline Used to induce sputum Osmolarity - hypertonic Draws fluid out of interstitial space to enhance production Can cause bronchospasms

Mucokinetics (to move mucus)

  Mucolytics        Acetylcysteine Mucomyst Works by breaking down disulfide bonds of mucus Dose: 10% or 20% Indicated for thick mucoid secretions Should be used with bronchodilator May cause bronchospasm and/or nausea Discard 96 hours after being opened

Mucokinetics (to move mucus)

  Mucolytics (cont)  Sodium bicarbonate Raises ph of sputum   Viscosity breaks down 2-5 ml of 2% solution, 3-4 times a day

Mucokinetics (to move mucus)

  Mucolytics (cont)  Deoxyribonuclease Dornavac    Proteolytic enzyme breaks down DNA bonds in sputum Reduces viscosity of sputum 50,000 – 100,000 units aerosolized up to 4 times a day

Mucokinetics (to move mucus)

  Mucolytics (cont)   Dornase alfa Pulmozyme Genetically engineered peptide proteolytic enzyme    Breaks down extracellular dna in purulent secretions Used to manage purulent mucoid secretions in patients with cystic fibrosis 2.5 mg (1 ampule) aerosolized daily

Surface active

 Ethanol        Ethyl alcohol (ETOH) Dose: 5-15 ml of 30% - 50% every 30 minutes for two to four treatments Delivered by SVN or IPPB Indicated for pulmonary edema     Alters surface tension thus popping bubbles May cause Bronchospasm Irritation Dehydration Alcohol intoxication Contraindicated in patients taking Antabuse

  

Equipment for administering mucokinetics & mucolytic agents

Small volume nebulizers Large volume nebulizers USN